ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Extended-Release Tacrolimus Therapy Is Effective and Safe in De Novo Kidney Transplant Recipients from Living and Expanded, Standard, or after Cardiac Death Deceased Donors

A. Andrés, E. Gonzalez, N. Polanco, L. Garcia-Puente, J. Morales, M. Molina, E. Gutierrez-Solis, A. Hernandez, A. Sevillano, M. Praga

Nephrology, Hospital 12 de Octubre, Madrid, Spain

Meeting: 2013 American Transplant Congress

Abstract number: C1344

Related Abstracts
  • Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial
  • 1-Year Outcomes of a Prospective, Open Label, Randomized, Controlled Trial of Standard vs Extended-Release Tacrolimus as Maintenance Monotherapy in Kidney Transplantation after Alemtuzumab Induction with Rapid Steroid Withdrawal (TAESR Trial)

Nonadherence is one of the most important causes of late renal graft loss. A single daily dose of tacrolimus in the morning beginning immediately after the transplant can improve adherence and improve long-term results. There have been few studies on initiating a single daily dose of tacrolimus immediately after renal transplant. We present our experience with extended-release tacrolimus (once a day dose) in 153 consecutive renal transplants with a minimum follow-up of 1 year in 4 renal transplant groups: Expanded Criteria Donor (ECD), Standard Criteria Donor (SCD), Donation After Cardiac Death Donor (DCDD) and Living Donors (LD). Acute rejection incidence was very low in all the groups. SCD group showed the highest rejection rate because it had the most hyperimmunized subjects. There were no significant differences in tacrolimus levels (ng/ml) at 7 days (7.5 vs. 6.8,), at 1 month (11.9 vs. 11.2) or at 3 months (8.9 vs. 10.1), respectively, between patients with and without rejection. At 1 year, graft survival was 91% (death-uncensored), patient survival 95% and SCr 1.4±0.4 mg%. Cumulative incidence of new onset diabetes after transplantation was 19%. A total of 22% of the patients had an infection requiring hospitalization.

  ECD N=58 SCD N=52 DCDD, N=31 LD, N=12
Recipient age (yr) 71±6 46±12 46±12 42±15
Retransplant N(%) 6(10) 21(40) 3(10) 1(8)
Incidence of PRAmax >20%/>50% (%/%) 4% / 0% 33% / 17% 10% /0% 9% /0%
Mean PRA max/curret (%/%) 3/0,1 18/6 2/4 2/2
IS Quadruple Therapy with Thymo N(%) 1(2) 14 (27%) 0(0%) 1(8%)
IS Sequential with Thymo N(%) 0(0) 0(0) 31(100) 0(0)
Acute Rejection N (%) 5(8) 10(19) 2(6) 1(8)

Extended-release tacrolimus (once a day dose) administered immediately after renal transplant in patients receiving a kidney from ECD, SCD, DCDD or LD is effective and safe, with very low rates of acute rejection, diabetes and severe infections and excellent graft and patient survival.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Andrés A, Gonzalez E, Polanco N, Garcia-Puente L, Morales J, Molina M, Gutierrez-Solis E, Hernandez A, Sevillano A, Praga M. Extended-Release Tacrolimus Therapy Is Effective and Safe in De Novo Kidney Transplant Recipients from Living and Expanded, Standard, or after Cardiac Death Deceased Donors [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/extended-release-tacrolimus-therapy-is-effective-and-safe-in-de-novo-kidney-transplant-recipients-from-living-and-expanded-standard-or-after-cardiac-death-deceased-donors/. Accessed January 16, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • Hyperkalemia in the Early Post Renal Transplant Period
  • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.